Company Overview


HepC Therapeutics Inc. (Superinfection) is a privately-held biotechnology firm based in Budapest, Hungary. The Company was founded as an Ltd in 2005 and converted to incorporation in 2014. Shortly after its foundation, HepC Therapeutics Inc. (Superinfection) has established a strategic alliance with VectorLogics, Inc. (VLI) in the USA. Based upon the IBDV technology (see below) and science VLI has raised almost $400 thousand from grants and invested its own scientific know-how to progress the project. Since VLI’s merger with DNAtrix, Inc. in 2012, the VLI IBDV vector portfolio was transferred to ImiGene, Inc. of Delaware, USA. Superinfection has acquired the IBDV vector portfolio and know-how under a new licensing agreement with ImiGene for equity stake in Superinfection. Superinfection’s USA business office is now located in Rockville, Maryland.

Superinfection is a biotechnology company focused on the development and commercialization of antiviral biologic products. Its lead clinical program is targeting advanced chronic HBV patients in order to provide functional cure during a finite course of treatment that would prevent the development of HCC. Furthermore, we are targeting HBV/HCV co-infected patients in order to treat HCV hepatitis without reactivation of HBV replication. Around 200.000 to 400.000 HBV/HCV coinfected individuals are in the United States alone[1] but many millions worldwide. The SIT platform technology could also mitigate the world-changing effects of the next flu pandemic, for which we aren’t ready to keep the world safe.

[1] Gish RG: HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. Gastroenterol Hepatol (N Y) 2017, 13:292-295.